Intra-Cellular Therapies Inc. (NASDAQ:ITCI) went down by -7.50% from its latest closing price compared to the recent 1-year high of $43.56. The company’s stock price has collected -11.42% of loss in the last five trading sessions. Press Release reported on 10/02/20 that New Ventures Funds Rebrands as Scientia Ventures
Is It Worth Investing in Intra-Cellular Therapies Inc. (NASDAQ :ITCI) Right Now?
Plus, the 36-month beta value for ITCI is at 1.61. Opinions of the stock are interesting as 10 analysts out of 10 who provided ratings for Intra-Cellular Therapies Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
Even if you’re not actively in crypto, you deserve to know what’s actually going on...
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets aren already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.
The average price from analysts is $54.33. ITCI currently public float of 60.35M and currently shorts hold a 11.17% ratio of that float. Today, the average trading volume of ITCI was 1.82M shares.
ITCI’s Market Performance
ITCI stocks went down by -11.42% for the week, with a monthly jump of 30.97% and a quarterly performance of 1.10%, while its annual performance rate touched 196.51%. The volatility ratio for the week stands at 5.01% while the volatility levels for the past 30 days are set at 7.11% for Intra-Cellular Therapies Inc.. The simple moving average for the period of the last 20 days is -12.06% for ITCI stocks with a simple moving average of 8.89% for the last 200 days.
Analysts’ Opinion of ITCI
JP Morgan, on the other hand, stated in their research note that they expect to see ITCI reach a price target of $26. The rating they have provided for ITCI stocks is “Neutral” according to the report published on January 31st, 2020.
Canaccord Genuity gave a rating of “Buy” to ITCI, setting the target price at $65 in the report published on December 24th of the previous year.
ITCI Trading at 5.31% from the 50-Day Moving Average
After a stumble in the market that brought ITCI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -45.34% of loss for the given period.
Volatility was left at 7.11%, however, over the last 30 days, the volatility rate increased by 5.01%, as shares surge +30.68% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.47% upper at present.
During the last 5 trading sessions, ITCI fell by -11.42%, which changed the moving average for the period of 200-days by +85.44% in comparison to the 20-day moving average, which settled at $27.35. In addition, Intra-Cellular Therapies Inc. saw -30.60% in overturn over a single year, with a tendency to cut further losses.
Reports are indicating that there were more than several insider trading activities at ITCI starting from Alafi Christopher D, who purchase 49,500 shares at the price of $29.60 back on Sep 14. After this action, Alafi Christopher D now owns 4,743,770 shares of Intra-Cellular Therapies Inc., valued at $1,465,200 using the latest closing price.
Alafi Christopher D, the Director of Intra-Cellular Therapies Inc., purchase 21,000 shares at $28.08 during a trade that took place back on Sep 11, which means that Alafi Christopher D is holding 4,694,270 shares at $589,680 based on the most recent closing price.
Stock Fundamentals for ITCI
Current profitability levels for the company are sitting at:
- -254090.46 for the present operating margin
The net margin for Intra-Cellular Therapies Inc. stands at -243713.69. The total capital return value is set at -57.48, while invested capital returns managed to touch -55.46. Equity return is now at value -60.60, with -51.30 for asset returns.
Based on Intra-Cellular Therapies Inc. (ITCI), the company’s capital structure generated 11.87 points at debt to equity in total, while total debt to capital is 10.61. Total debt to assets is 9.21, with long-term debt to equity ratio resting at 10.23. Finally, the long-term debt to capital ratio is 9.15.
When we switch over and look at the enterrpise to sales, we see a ratio of 27,924.20, with the company’s debt to enterprise value settled at 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.36.